Glaxosmithkline Share Price | |
---|---|
Price | 1,502.00 |
Bid | 1,501.50 |
Ask | 1,502.00 |
Change | -1.50 (-0.10%) |
Volume | 1,480,529 |
Open | 1,513.50 |
High | 1,513.50 |
Low | 1,497.00 |
Prev. Close | 1,503.50 |
Currency | GBX |
---|---|
Issue Country | GB |
Shares in Issue | 4.08b |
Market Capitalisation | £61.25b |
Market Size | 1,500 |
52 Week High | 1,820.00 |
52 Week High Date | 15-May-2024 |
52 Week Low | 1,302.60 |
52 Week Low Date | 11-Jul-2023 |
# Trades | 4,502 |
---|---|
Vol. Sold | 792,275 |
Sold Value | £11.93m |
Vol. Bought | 657,717 |
Bought Value | £9.89m |
PE Ratio | 12.35197 |
Earnings | 121.60 |
Dividend | 55.50 |
Yield | 3.695% |
Date | Time | Trade Prc | Volume | Buy/Sell | Bid | Ask | Value | |
---|---|---|---|---|---|---|---|---|
03-Jul-24 | 14:59:10 | 1,501.50 | 1,155 | Sell* | 1,501.50 | 1,502.00 | 17.34k | A Automatic Execution |
03-Jul-24 | 14:59:10 | 1,501.50 | 21 | Sell* | 1,501.50 | 1,502.00 | 315.32 | A Automatic Execution |
03-Jul-24 | 14:58:46 | 1,501.50 | 415 | Sell* | 1,501.50 | 1,502.00 | 6,231 | O Ordinary Trade was executed as an SI |
03-Jul-24 | 14:58:45 | 1,501.50 | 568 | Sell* | 1,501.50 | 1,502.00 | 8,529 | O Ordinary Trade was executed as an SI |
03-Jul-24 | 14:57:57 | 1,501.50 | 681 | Sell* | 1,501.50 | 1,502.00 | 10.23k | O Ordinary Trade was executed as an SI |
03-Jul-24 | 14:57:55 | 1,502.00 | 48 | Buy* | 1,501.50 | 1,502.50 | 720.96 | A Automatic Execution |
03-Jul-24 | 14:57:55 | 1,502.00 | 820 | Buy* | 1,501.50 | 1,502.00 | 12.32k | A Automatic Execution |
03-Jul-24 | 14:57:55 | 1,502.00 | 519 | Buy* | 1,501.50 | 1,502.00 | 7,795 | A Automatic Execution |
03-Jul-24 | 14:57:22 | 1,501.50 | 278 | Buy* | 1,501.50 | 1,502.00 | 4,174 | A Automatic Execution |
03-Jul-24 | 14:57:22 | 1,501.50 | 393 | Buy* | 1,501.00 | 1,501.50 | 5,901 | A Automatic Execution |
Announced | Traded | Action | Notifier | Price | Currency | Amount | Holding |
---|---|---|---|---|---|---|---|
21-Jun-24 | 20-Jun-24 | Buy | Jonathan Symonds held the position of Non-Executive Chairman at the time of this trade.Jonathan Symonds | 1,614.53 | GBX | 2,000 | 56,143 |
21-Jun-24 | 20-Jun-24 | Buy | Harry (Hal) C. Dietz held the position of Independent Non-Executive Director at the time of this trade.Harry (Hal) C. Dietz | 40.76 | USD | 225 | 3,343 |
21-Jun-24 | 20-Jun-24 | Buy | Anne Beal held the position of Independent Non-Executive Director at the time of this trade.Anne Beal | 40.76 | USD | 225 | 3,600 |
21-Jun-24 | 20-Jun-24 | Buy | Jesse Goodman held the position of Independent Non-Executive Director at the time of this trade.Jesse Goodman | 40.76 | USD | 225 | 11,382 |
21-Jun-24 | 20-Jun-24 | Buy | Vishal Sikka held the position of Independent Non-Executive Director at the time of this trade.Vishal Sikka | 40.76 | USD | 1,179 | 253,467,687 |
At GSK, we unite science, technology and talent to get ahead of disease together